Cluenex
Log inStart free
All stocks · Healthcare · Pharmaceuticals

AbbVie ABBV

AbbVie scores good on business quality (7.1 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$276.47Oct 9, 2026
Business qualityGood
Next earningsOct 30, 2026
Insiders, 90 daysSelling

Why it matters

  1. What AbbVie does

    AbbVie develops and sells specialized pharmaceutical drugs globally, relying on hospitals, physicians, and insurers to fund its immunology and oncology portfolio.

  2. What it does best

    AbbVie dominates immunology commercialization, generating a gross margin of 72.8% that matches AMGN's 74.3%. This edge stems from entrenched physician relationships and massive clinical trial scale that smaller biotechs cannot easily replicate.

  3. The main risk

    A massive net debt load of $62.2B creates ongoing vulnerability if pipeline assets fail to replace fading legacy revenues.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityStrong

Operating margin hits the 90th sector percentile while free cash flow margin sits in the 86th percentile, expanding as high-margin specialty drugs scale.

MoatStrong

Operating in the top decile of its sector at the 90th percentile for operating margin, AbbVie locks in enterprise buyers with patented biologics and complex manufacturing barriers.

GrowthSlow

Revenue growth of 8.6% is outpacing historical periods, driven by newer specialty pharma segments offsetting older drug declines.

Financial healthStrong

Net debt sits at $62.2B while interest coverage is 7.8x. Free cash flow reaches $18.2B, showing steady cash generation despite heavy leverage.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

1 sold $8.2M outside pre-planned sales.

Our sealed record on ABBV

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is ABBV a good business?

AbbVie scores good on the Cluenex quality check (7.1 of 10), measured against its own industry. Profitability is strong, moat strong, growth slow and financial health strong.

Are insiders buying ABBV?

In the last 90 days of SEC Form 4 filings: 1 sold $8.2M outside pre-planned sales.

When does ABBV report earnings?

Oct 30, 2026.

For members

See ABBV today

  • Today's verdict on ABBV, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “AbbVie (ABBV)”, https://cluenex.com/stocks/abbv/, data as of Oct 10, 2026.